摘要 ： 9月11日，作为BCEIA 2025同期分论坛之一，微全分析分论坛召开，论坛为期2天，首日即吸引近百人参会交流。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪 器 信 息 网 讯 2025 年 9 月 10 日 ， 第 二 十 一 届 北 京 分 析 测 试 学 术 报 告 会 暨 展 览 会 （ The 21s t Beijing Conference & Exhibition on Ins trumental Anal y s i s，BCEIA 2025） 在北京·中国国际展览中心（顺义馆）盛大开幕。9月11日，作为BCEIA 2025同期分论坛之一， 微全分析分论坛召开，论坛为期2天，首日即吸引近百人参会交流。 论 坛 现 场 Ka z u m a M a w a t a ri W a s e d a U n i v e r s ity 报告：AI-based Concentration Dev ice and Sensor for Microfluidics 微流控技术在化学、生物学和医学领域的超灵敏分析方面展现出 ...

Industry Overview - The exosome industry in China is experiencing strong growth, with a market size projected to reach 2.279 billion yuan in 2024, representing a year-on-year increase of 22.72% [1][7]. - Exosomes are membrane vesicles released from cells that play a crucial role in intercellular communication, containing various biomolecules such as proteins, lipids, and nucleic acids [2][6]. Industry Chain - The upstream of the exosome industry includes sources like animal, plant, and microbial exosomes, along with necessary biological reagents and production equipment [6]. - The midstream focuses on the production and manufacturing of exosomes, while the downstream applications span medical, aesthetic, and research services [6]. Key Applications - In the medical field, exosomes are utilized for tumor treatment by modulating the tumor microenvironment and delivering drugs [7]. - Exosomes serve as ideal biomarkers for liquid biopsies due to their high stability, enabling dynamic monitoring of tumor progression [7]. - In the aesthetic sector, exosomes are leveraged for anti-aging products due to their active components and low immunogenicity [7]. Market Size - The continuous advancement in biotechnology and exploration of intercellular communication mechanisms have led to significant developments in emerging technologies like engineered exosomes and microfluidics [1][11]. - The exosome market in China is projected to grow significantly, with a market size of 2.279 billion yuan expected in 2024, reflecting a 22.72% increase from the previous year [1][11]. Key Companies - Beijing Enze Kangtai Biotechnology Co., Ltd. has established a leading position in the engineered exosome sector with its GMP production facility and extensive collaborations [8]. - Guodian (Beijing) Pharmaceutical Technology Co., Ltd. focuses on innovative drug development using iPS cells and exosomes, particularly for neurological and immune-related diseases [9]. Industry Development Trends - Technological innovations are expected to enhance the efficiency and precision of exosome extraction, purification, and detection, facilitating large-scale production [11]. - The application of exosomes in disease diagnosis and treatment is anticipated to expand, with specific biomarkers being utilized for early diagnosis and therapeutic delivery [12]. - Increased government support and the establishment of industry standards will lead to stricter quality control and production practices in the exosome sector [13].

| | | 微流控行业相关政策 | | --- | --- | --- | | 时间 | 政策名称 | 王要内容 | | 2023年12月 | 《关于全国推进紧密型 | 统筹建立县域内医学检验、医学影像、心 | | | | 病理诊断、消毒供应等资源共享中心;将 | | | 县域医疗卫生共同体建 | | | | 设的指导意见》 | 延伸到乡村,推行县层检查、上级诊断、 | | | | 加强检查检验、疾病诊断质量监测评价。 | | 2023年3月 | | 要求扎实推进医用耗材集中带量采购,按 | | | 《关于做好2023年医药 | 策的原则开展新批次国家组织高值医用耗 | | | 集中采购和价格管理工 | 提高集采精细化管理水平,创新完善集采 | | | 作的通知》 | 力提高报量准确性,强化落实优先使用中 | | | | 加强中选产品供应保障。 | | 2022年5月 | | 发展微流控芯片、细胞制备目动化等先进 | | | 《"十四五"生物经济 | 动抗体药物、重组蛋白、多肽、细胞和基 | | | 发展规划 » | 品等生物药发展,鼓励推进慢性病、肿瘤 | | | | 行性疾病等重大疾病和学儿病的原创药物 ...

Financial Performance - In H1 2025, the company reported revenue of 203 million yuan, a decrease of 23.91%, and a net profit attributable to shareholders of 12.4 million yuan, down 82.82% [1] - Q2 2025 revenue was 115 million yuan, a decline of 12.27%, with a net profit of 3.67 million yuan, down 88.72% [1] - The decline in revenue was primarily due to tariff impacts on U.S. business and a slowdown in government procurement, alongside decreased demand for mosquito products in Latin America and respiratory testing in domestic markets [1] Cost and Expense Analysis - The company's expense ratios for R&D, sales, management, and financial costs were 19.67%, 9.91%, 17.46%, and -6.38% respectively, with increases of 8.31, 5.67, 5.47, and 6.29 percentage points [1] - Profit margins were more adversely affected than revenue due to increased registration fees, employee stock plan costs, and reduced financial income [1] Product Development and Innovation - The company launched several new products in H1 2025, including four new drug testing reagents and a chikungunya virus testing reagent, enhancing its product pipeline [2] - Microfluidic technology has improved device portability and adaptability, achieving laboratory-level sensitivity while reducing costs by 60% [2] - The company is focusing on the development of cardiac markers, thyroid function, and nutritional products, with multi-item testing on a single chip already achieved [2] Strategic Initiatives - The company has strategically entered the brain-computer interface market through its subsidiary, investing in a company that targets treatment for severe depression [2] - The brain-computer interface market is expected to grow significantly due to policy support and technological breakthroughs, which could enhance the company's long-term growth prospects [2] Future Projections - Revenue projections for 2025-2027 are 585 million yuan, 731 million yuan, and 890 million yuan, with net profits of 108 million yuan, 166 million yuan, and 215 million yuan respectively [3] - Corresponding P/E ratios for 2025-2027 are expected to be 54.12, 35.17, and 27.27 [3]

金融界2025年8月16日消息，国家知识产权局信息显示，上海东富龙海崴生物科技有限公司取得一项名 为"一种基于微流控技术的纳米药物生产设备"的专利，授权公告号CN223221374U，申请日期为2024年 07月。 专利摘要显示，本实用新型涉及一种基于微流控技术的纳米药物生产设备，包括第一罐系统、第二罐系 统和混合系统；所述第一罐系统包括第一罐；所述第二罐系统包括第二罐；所述混合系统包括混合结 构，所述第一罐和所述第二罐共同连通所述混合结构。本实用新型的目的在于克服现有的缺陷而提供的 一种基于微流控技术的纳米药物生产设备，可以将药物充分混合，从而获得大小分布精确、包封率高的 纳米药物产品。 天眼查资料显示，上海东富龙海崴生物科技有限公司，成立于2016年，位于上海市，是一家以从事专用 设备制造业为主的企业。企业注册资本5000万人民币。通过天眼查大数据分析，上海东富龙海崴生物科 技有限公司参与招投标项目2次，财产线索方面有商标信息4条，专利信息66条，此外企业还拥有行政许 可5个。 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年3月4日， 芯易诊（CytoChip） 开发的 POCT血常规产品CitoCBC™ ，成为全球首款获得美国FDA 510(k)认证和CLIA豁免的卡片式 血常规。 即时血常规检测，提升诊疗体验 作为临床最常用的医学检验之一，血常规检测在美国市场需求旺盛，全美超过25万家CLIA豁免实验室可直接采用CitoCBC，在诊所、药店等 场景实现血常规检测，现场获取结果，大幅提升患者就诊体验。传统血常规设备难以满足CLIA豁免的"即插即用、免维护"要求，无法进入该 市场。 突破传统模式，打造全新诊所检测生态 长期以来，诊所血常规检测需外送至第三方实验室，年检测外送市场规模高达40亿美元。CitoCBC ® 凭借CLIA豁免优势，帮助诊所实现检测 能力、提升患者的诊断能力，同时保留检测收入。 在诊所常规检测项目中，大多数已有CLIA豁免产品，而血常规检测长期是唯一空白。CitoCBC ® 填补了这一关键缺口，成为诊所端完整 POCT检测体系的"最后一块拼图 ...